Timber Pharmaceuticals Announces Appointment of Dr. David Cohen and Dr. Lubor Gaal to Board of Directors
August 19 2020 - 4:10PM
via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the
“Company”) (NYSE American: TMBR), a biopharmaceutical company
focused on the development and commercialization of treatments for
orphan dermatologic diseases, today announced the appointment of
David Cohen, M.D. and Lubor Gaal, Ph.D. to its board of directors.
“We continue to add expertise and talent in the
areas of drug development and delivery to our team at Timber and
welcome Dr. Cohen and Dr. Gaal to the Board,” said John Koconis,
chief executive officer of Timber. “Dr. Cohen is a renowned
dermatologist who has contributed to the development of global
treatment guidelines and has played an important role in advancing
research in many rare dermatologic conditions. Meanwhile, Dr. Gaal
has extensive experience as a biotech entrepreneur with a
successful track record in securing assets and executing licensing
and partnering transactions. We look forward to working closely
with both as we advance our clinical development
pipeline.”
Dr. Cohen is the Charles C. and Dorothea E.
Harris Professor of Dermatology at New York University School of
Medicine, where he also serves as Chief of Allergy and Contact
Dermatitis, Vice Chairman of Clinical Affairs, and Director of
Occupational and Environmental Dermatology. He was a founding board
member for the American Acne and Rosacea Society and previously
served as President of the American Dermatological Association, the
American Contact Dermatitis Society, the Dermatology Section of the
New York Academy of Medicine, and the New York Dermatological
Association. Dr. Cohen has also served on numerous boards including
Kadmon, Dermira, Vyteris, and Connetics. He received a B.S. in
biomedical science from the City University of New York, an M.D.
from State University of New York at Stony Brook School of
Medicine, and an M.P.H. in environmental science from Columbia
University School of Public Health.
Dr. Gaal brings more than two decades of
business development, external innovation, and licensing experience
in biotechnology and biopharmaceuticals. He is currently Senior
Vice President and Head of Europe for Locust Walk where he is
responsible for executing licensing, M&A, and financing
transactions for biopharma companies around the globe. Dr. Gaal
previously served as Head of External Innovation and Licensing for
Almirall and held various roles at Bristol-Myers Squibb including
Head of Europe, Global Search and Business Development. He has also
held executive management roles at NEURO3D, Vectron Therapeutics,
Berlex Laboratories, Burrill & Company, and Sandoz. Dr. Gaal
has a B.Sc. in Neurobiology from the University of Sussex and a
Ph.D. in Neurosciences from the University of California.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases.
The Company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and localized scleroderma. For more
information, visit www.timberpharma.com
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Form 10-Q filed on
August 18, 2020 and its other filings with the Securities and
Exchange Commission. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc. John Koconis Chief Executive
Officerjkoconis@timberpharma.com
Investor Relations:Stephanie PrincePCG Advisory(646)
762-4518sprince@pcgadvisory.com
Media Relations: Adam DaleyBerry & Company Public Relations
(212) 253-8881adaley@berrypr.com
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Sep 2023 to Sep 2024